Pfizer, the largest US drug-maker, reported quarterly revenue that missed estimates as sales of its key drugs fell short of expectations. Sales of breast cancer drug Ibrance, which is expected to face competition from rival Novartis’s Kisqali, rose more than 58% to $679m, but missed the consensus estimate of $682m, according to Barclays. "Key franchises came in well below expectations, raising concerns about Pfizer’s ability go grow in the absence of mergers and acquisitions," Goldman Sachs analysts said. Sales of the company’s arthritis drug, Xeljanz, were particularly weak, the analysts said, adding that cancer drug Xtandi and its Prevnar vaccine also came in lower than expectations. Pfizer said three fewer selling days in the quarter, compared with last year, reduced sales by about $300m, surprising some Wall Street analysts. "Pfizer calls out a deficit of selling days ... Given that multiple major products fell just to the short side of our estimates, we are inclined to agree," ...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now